title: [Arterial infusion chemotherapy in pelvic space for advanced rectal cancer].
abstract: Three rectal cancer patients were treated with arterial infusion chemotherapy through the internal iliac artery. Two patients with pelvic recurrences unresectable after APRA were treated with intensive chemotherapy and the other patient with neoadjuvant chemotherapy. In all cases, 5-FU (500 mg/ body/day) was administered continuously for 5 days or 14 days. We attempted three methods for this procedure which were a bilateral catheterization to the internal iliac artery, a single catheterization with an embolization to the other internal iliac artery and a single catheterization without the embolization. As the result of this treatment, in the resected specimen with neoadjuvant case, histological necrosis was found in 50% in the main tumor and the metastatic lymph nodes. One patient with pelvic recurrence showed a partial response in CT imaging, but died one year later of the recurrence around the external iliac artery. The other patient with pelvic recurrence treated with the bilateral catheterization had no efficacy on CT imaging, but his CEA level has decreased at present. It was concluded that arterial infusion chemotherapy was effective for advanced rectal cancer and the pelvic recurrences. However, the efficacy of this treatment is limited to the area to which the drugs are delivered. Thus, it is important that the method and the location of the catheterization are determined adequately for each case.
authors.affiliation: 2nd Dept. of Surgery, Chiba University School of Medicine.
authors.forename: W
authors.initials: W
authors.lastname: Takayama
authors.forename: H
authors.initials: H
authors.lastname: Imazeki
authors.forename: S
authors.initials: S
authors.lastname: Okazumi
authors.forename: A
authors.initials: A
authors.lastname: Takeda
authors.forename: S
authors.initials: S
authors.lastname: Miyazaki
authors.forename: T
authors.initials: T
authors.lastname: Fukunaga
authors.forename: K
authors.initials: K
authors.lastname: Iwasaki
authors.forename: K
authors.initials: K
authors.lastname: Shutou
authors.forename: K
authors.initials: K
authors.lastname: Nakajima
authors.forename: H
authors.initials: H
authors.lastname: Aoyama
authors.forename: K
authors.initials: K
authors.lastname: Shinotou
authors.forename: H
authors.initials: H
authors.lastname: Matsuzaki
authors.forename: T
authors.initials: T
authors.lastname: Maeda
authors.forename: K
authors.initials: K
authors.lastname: Isono
mesh_terms: D000931:Antidotes / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007083:Iliac Artery; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage; D008207:Lymphatic Metastasis; D010386:Pelvic Neoplasms / Q000188:drug therapy* / Q000556:secondary; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D005472:Fluorouracil